Nyotran liposomal nystatin data

ARNX presented pharmacokinetic data in humans and findings in neutropenic mice at the Interscience Conference on Antimicrobial Agents and Chemotherapy in New Orleans. The agent is in Phase III testing in comparison with amphotericin B in patients with presumed fungal infections and in an open label Phase II/III trial in candidemia.

Therapeutic blood levels were attained at 2 mg/kg, given as an intravenous infusion every other day, and the agent was well tolerated up to 7 mg/kg, a Phase I trial showed. ...